2015
DOI: 10.1189/jlb.4a1014-483rr
|View full text |Cite
|
Sign up to set email alerts
|

Limited specificity of IRF3 and ISGF3 in the transcriptional innate-immune response to double-stranded RNA

Abstract: The innate immune response is largely initiated by pathogen-responsive activation of the transcription factor IRF3. Among other target genes, IRF3 controls the expression of IFN-β, which triggers the activation of the transcription factor ISGF3 via the IFNAR. IRF3 and ISGF3 have been reported to control many of the same target genes and together, control the antimicrobial innate-immune program; however, their respective contributions and specificities remain unclear. Here, we used genomic technologies to chara… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

6
24
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
6
1

Relationship

3
4

Authors

Journals

citations
Cited by 29 publications
(30 citation statements)
references
References 50 publications
6
24
0
Order By: Relevance
“…Thus datasets from additional pertubation studies may lead to the inclusion of additional TFs and regulatory mechanisms in future iterations of the models. For example, this may reveal distinctions in transcriptional control by NFκB family members RelA vs cRel vs RelB (Almaden et al, 2016; Alves et al, 2014) or IRF3 vs ISGF3 (Ourthiague et al, 2015). Further, challenging the model to account for longer timecourses may require inclusion of a variety of late inducible TFs such as ATF3 (Gilchrist et al, 2006), CEBPβ and CEBPδ (Litvak et al, 2009) as well as LDTFs leading to the establishment of poised enhancers and promoters (Garber et al, 2012; Kaikkonen et al, 2013; Miele and Dekker, 2008).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Thus datasets from additional pertubation studies may lead to the inclusion of additional TFs and regulatory mechanisms in future iterations of the models. For example, this may reveal distinctions in transcriptional control by NFκB family members RelA vs cRel vs RelB (Almaden et al, 2016; Alves et al, 2014) or IRF3 vs ISGF3 (Ourthiague et al, 2015). Further, challenging the model to account for longer timecourses may require inclusion of a variety of late inducible TFs such as ATF3 (Gilchrist et al, 2006), CEBPβ and CEBPδ (Litvak et al, 2009) as well as LDTFs leading to the establishment of poised enhancers and promoters (Garber et al, 2012; Kaikkonen et al, 2013; Miele and Dekker, 2008).…”
Section: Discussionmentioning
confidence: 99%
“…Primary BMDMs were prepared by culturing bone marrow cells from femurs of male or female 8–12 week old WT mice in L929-conditioned medium by standard methods (Cheng et al, 2011; Ourthiague et al, 2015). BMDMs were stimulated on day 8.…”
Section: Star Methodsmentioning
confidence: 99%
“…Expression of a subset of ISGs can be induced in the absence of IFN signaling (55,56). It is likely to be at least partially attributed to similar and overlapping consensus DNA-binding motifs for the interferon regulatory factor (IRF) family, most notably IRF3 and IRF7, which are key regulators of type I IFN production, and for IFN-stimulated gene factor 3 (ISGF3), which promotes the expression of many ISGs in response to IFN signaling (57)(58)(59)(60). For example, an IRF3 chromatin immunoprecipitation sequencing (ChIP-seq) experiment with adenovirus-infected human primary bronchial/tracheal epithelial cells demonstrated IRF3 binding to the promoter region of induced ISGs, including MX1 and ISG15, which have the IFNstimulated response element (ISRE) bound by IRFs and ISGF3 in the promoter regions (61).…”
Section: Downloaded Frommentioning
confidence: 99%
“…Activated IRF3 induces IFN-β gene expression which, in turn, activates JAK/STAT signaling, leading to the transcription of a variety of ISGs (39). Here, we showed that statins inhibit the phosphorylation of both IRF3 and STAT1 in poly(I:C)-treated macrophages (Fig.…”
Section: Discussionmentioning
confidence: 52%
“…Hyperlipidemic mice exhibit altered immune responses (23,24,33). Atorvastatin improved plaque stability in ApoE-knockout mice (39), and exerted hypolipidemic and anti-inflammatory action in ApoE/LDL receptor-knockout mice (40). However, to our knowledge, the effects of statins on the antiviral immune response in hyperlipidemic mice have not been evaluated.…”
Section: Discussionmentioning
confidence: 99%